· Trials · Trials Desk
NCT06041217 published full Phase 3 results for semaglutide in obesity (mean -12.2% body weight at week 44, 80.5% achieved ≥5%). Roche registered a Phase 2 of petrelintide + enicepatide; Altimmune's pemvidutide NASH Phase 2 marked completed; Amgen's maridebart cafraglutide expanded into ASCVD, HFpEF, and OSA Phase 3.
This brief is part of the Novusyn Research news desk. We track peptide clinical readouts, regulatory actions, and pharma developments in neutral, evidence-led language for scientifically literate readers.
For related context, see the full news desk, clinical trials tracker, regulation tracker, compound directory, and guides library.